Clinical Trial

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-07-22; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT07093801
Lead Sponsor Novartis Pharmaceuticals
Conditions Metastatic Castration Resistant Prostate Cancer
Enrollment 300 participants
Start Date 2025-07-30
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15